Our new infographic provides a unique view into diligence requirements for private-target life sciences M&A transactions from 2008 to 2017. Built from the SRS Acquiom database of over 130 life sciences deals with more that $24 billion in potential milestone payments, this snapshot from our 2017 SRS Acquiom Life Sciences M&A Study will provide insight into common questions including:
- What is the most common diligence requirement relating to earnouts for life sciences deals?
- What are the common variations in Commercially Reasonable Efforts (CRE)?
- What are the specific requirements seen in most deals?
- What do most agreements state about reporting and meetings?